Zevra Therapeutics (ZVRA) Cash from Financing Activities (2014 - 2026)

Zevra Therapeutics has reported Cash from Financing Activities for 13 years, with the latest figure at -$52.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 3385.87% year-over-year to -$52.8 million; the trailing twelve-month figure through Mar 2026 stood at -$42.3 million (down 151.33% YoY), and the FY2025 full-year result was $12.1 million, down 85.31% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$52.8 million, down from $2.5 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $64.8 million in Q3 2024, with the low at -$52.8 million in Q1 2026.
• Historically, Cash from Financing Activities has averaged $4.9 million across 5 years, with a median of $1.5 million in 2025.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 5605.03% — and 2026, when it plunged 3385.87%.
• Zevra Therapeutics' Cash from Financing Activities stood at -$257000.0 in 2022, then soared by 2047.08% to $5.0 million in 2023, then tumbled by 84.09% to $796000.0 in 2024, then soared by 219.85% to $2.5 million in 2025, then slumped by 2174.0% to -$52.8 million in 2026.
• The last three Cash from Financing Activities figures came in at -$52.8 million (Q1 2026), $2.5 million (Q4 2025), and $6.5 million (Q3 2025), per Business Quant data.